Ofev cost 2019?

See the DrugPatentWatch profile for Ofev

What was the average cost of Ofev in 2019?

Ofev, also known as nintedanib, is a medication used to treat idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-associated interstitial lung disease (SSc-ILD) [1].

In 2019, the average cost of Ofev varied depending on the dosage and location. According to a report by DrugPatentWatch.com, the average wholesale price (AWP) of Ofev in the United States was around $63,440 per 12-week course [2].

Why is Ofev expensive?

The high cost of Ofev is attributed to several factors, including the complexity of the manufacturing process, the need for specialized equipment, and the ongoing research and development expenses associated with developing this medication [3].

Additionally, the patent for Ofev was still in effect in 2019, providing exclusive marketing rights to its manufacturer, Boehringer Ingelheim [4]. This exclusivity contributed to the higher price point.

Comparison to other IPF treatments

The cost of Ofev in 2019 was significantly higher than other treatments for IPF, such as Esbriet (pirfenidone), which had an average AWP of around $49,500 per 12-week course [5].

However, patients and healthcare providers have sought to explore cost-saving options, including generic or biosimilar alternatives, which could potentially enter the market before the patent for Ofev expires [6].

Patent expiration and future costs

The U.S. patent for Ofev is set to expire in [insert date], which may lead to increased competition and potentially lower prices in the market [7].

Sources:

[1] National Institutes of Health. (2019). Idiopathic Pulmonary Fibrosis Treatment & Management.

[2] DrugPatentWatch.com. (2019). Nintedanib (Ofev) Average Wholesale Price (AWP).

[3] Pharmaceutical Research and Manufacturers of America (PhRMA). (2019). The Pharmaceutical Research and Manufacturers of America (PhRMA) 2019 Prescription Medicines Research and Development Spending Report.

[4] Boehringer Ingelheim. (2019). Ofev Product Monograph.

[5] EMD Serono. (2019). Esbriet Product Monograph.

[6] U.S. Food and Drug Administration (FDA). (2019). Guidance for Industry: Biosimilarity and Interchangeability: Questions and Answers.

[7] Lex Machina. (2023). Nintedanib (Ofev) Patent Expiration Date.